M-RIVAROXABAN 20 MG
RIVAROXABAN : 20 MG · DIN 02551632 · MANTRA PHARMA INC
Health Canada status: MARKETED
What is M-RIVAROXABAN?
M-RIVAROXABAN 20 MG contains RIVAROXABAN : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02551632, held by MANTRA PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 19-Dec-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is M-RIVAROXABAN used for?
Prevention of VTE (THR/TKR); treatment/prevention of DVT and PE; stroke prevention in atrial fibrillation; vascular protection in CAD/PAD (with ASA); pediatric VTE treatment (weight >= 30kg).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02551632 |
|---|---|
| Brand name | M-RIVAROXABAN |
| Generic / active ingredient | RIVAROXABAN : 20 MG |
| Manufacturer | MANTRA PHARMA INC |
| Strength | 20 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | B01AF01 RIVAROXABAN |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 19-Dec-2024 |
How is it administered?
Varies by indication: 2.5 mg bid (with ASA), 10 mg od, 15 mg od/bid, or 20 mg od. 15 mg and 20 mg tablets must be taken with food for adults. Pediatric dosing is weight-based (15 mg or 20 mg od).
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text (Section 11 header present but content not shown).
How is it supplied?
Not explicitly detailed in the provided text (mentions 2.5 mg, 10 mg, 15 mg, and 20 mg tablets).
Contraindications
Clinically significant active bleeding; lesions/conditions at risk of major bleeding; concomitant strong CYP 3A4 and P-gp inhibitors; other anticoagulants; hepatic disease with coagulopathy; pregnancy/nursing.
Warnings and precautions
Increased risk of bleeding. Not recommended for patients with prosthetic heart valves. Premature discontinuation increases risk of thrombotic events. Spinal/epidural hematoma risk.
What can be used instead?
Other Canadian products sharing ATC code B01AF01 RIVAROXABAN. 68 of 97 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-RIVAROXABAN | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02527995 |
| AG-RIVAROXABAN | 15 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02528002 |
| AG-RIVAROXABAN | 2.5 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02555255 |
| AG-RIVAROXABAN | 20 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02528010 |
| APO-RIVAROXABAN | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02470497 |
| APO-RIVAROXABAN | 15 MG | TABLET | APOTEX INC | MARKETED | DIN 02470500 |
| APO-RIVAROXABAN | 2.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02541734 |
| APO-RIVAROXABAN | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02470519 |
| AURO-RIVAROXABAN | 10 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02560356 |
| AURO-RIVAROXABAN | 15 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02560364 |
Who else supplies RIVAROXABAN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. RIVAROXABAN appears in 2966 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.